Steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 october 2004 please refer to module 8B. 
• 
• 
• 
On 21 January 2000 the Marketing Authorisation Holder submitted to the EMEA an application 
for a Type I variation relating to the increase of batch size of the active substance. On 15 March 
2000  the  EMEA  has  notified  the  European  Commission  that  the  change  was  accepted.  
The European Commission amended the Decision on 27 April 2000. 
On  12  June  2000  the  Marketing  Authorisation  Holder  notified  the  EMEA  of  its  intention  to 
introduce  changes  in  the  Labelling  and  the  Package  Leaflet  not  connected  to  the  Summary of 
Product  Characteristics. On 7 August  2000 the EMEA has notified the European Commission 
that  the  changes  were  accepted.  The  European  Commission  amended  the  Decision  on  
29 September 2000. 
On 25 August 2000 the Marketing Authorisation Holder submitted to the EMEA an application 
the  manufacturing  process.  
for  a  Type  I  variation  relating 
On  19  October  2000  the  EMEA  has  notified  the  European  Commission  that  the  change  was 
accepted. 
to  a  minor  change 
in 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
reactions  available 
Change in the sterility test methodology for the active substance 
Changes in Summary of Product Characteristics (SPC), Labelling 
and Package leaflet (PL). Following 1st PSUR (14 August 1999 - 13 
February 2000), as well as the discussion held at the PVWP in July 
2000:  
- In section 4.4 (Special warnings and special precautions for use) of 
the  SPC,  to  amend  an  existing  warning  on  the  risk  of  allergic  and 
anaphylactic reactions and the necessity to have medications for the 
treatment  of  severe  hypersensitivity 
for 
immediate use following administration of palivizumab. 
- In section 4.8 (Undesirable effects), to add “Apnoea” in the list of 
rare  ADRs 
reported  during  post-marketing  experience,  and 
“Anaphylaxis”, as very rare ADRs (<1/10.000).  
- To amend the PL, in accordance with the information added in the 
SPC. 
Moreover, the MAH took the opportunity of this variation to 
implement the newly assigned ATC code in section 5.1 of the SPC 
and to bring the documents in line with the QRD templates. 
Changes to comply with note for guidance on minimising the risk of 
transmitting Animal spongiform Encephalopathy 
Extension of shelf-life from 2 years to 30 months as foreseen at time 
of authorisation 
Extension of Shelf-life from 30 months to 3 years as foreseen at time 
of authorisation 
Change in the SPC following 4th PSUR (14 February 2001 – 19 June 
2000) to add “Urticaria” to the list of very rare ADRs in section 4.8 
(Undesirable Effects). 
Change in the specifications of the active substance 
This notification relates to address changes affecting the PL, namely 
to update the address of the local representatives in all languages and 
to correct spelling mistakes in the labelling. 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
I-0004 
II-0005 
I 
II 
26.01.01 
25.01.01 
Commission 
Decision 
Issued/amended 
on 
- 
01.06.01 
II-0006 
I-0007 
I-0008 
II-0009 
I-0010 
N-0011 
II 
I 
I 
II 
I 
N 
18.10.01 
- 
21.06.01 
24.08.01 
21.12.01 
05.03.02 
21.02.02 
24.05.02 
17.07.02 
15.01.03 
- 
03.02.03 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended for procedures 
finalised before 1 October 2003. In accordance with Article 6 of Commission Regulation (EC) No 1085/2003 for 
procedures finalised after 1 October 2003 : I refers to a minor variation (Type I variation); II refers to a major 
variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 
of the Regulation; X refers to an Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/2 
EMEA 2004 
 
 
 
 
                                                            
 
Update of the SPC section 4.4 (Special warnings and special 
precautions for use) and 5.1 (Pharmacodynamic properties) 
following the CPMP assessment of clinical studies related to the 
possible risk of enhanced RSV infection. Additional changes are 
proposed for section 4.4, to update SPC information on anaphylaxis. 
An amendment to the SPC for Synagis to reflect data now available 
following the conclusion of clinical study prophylaxis of Respiratory 
Syncytial  Virus  in  Children  with  Congential  Heart  Disease.  In  line 
with  this,  amendments  are  proposed  to  the  SPC,  Sections  4.1 
“Therapeutic  Indications”,  4.4  “Special  warnings  and  special 
precautions for use”, 4.5 “Interaction with other medicinal products 
and  other  forms  of  interaction”,  4.8  “Undesirable  effects”,  5.1 
“Pharmacodynamic 
“Pharmacokinetic 
properties”.  
Relevant changes are also proposed for the PL. 
This notification relates to address changes affecting the PL, namely 
to update the address of the local representatives in all languages. 
Update  of  SPC 
(Posology  and  method  of 
administration),  4.4  (Special  warnings  and  special  precautions  for 
use),  4.8 
(Pharmacodynamic 
properties)  based  on  new  data  regarding  administration  of  greater 
than  5  doses  of  palivizumab  in  a  single  RSV  season  and  on  the 
safety of more than 5 doses of palivizumab in a single RSV season.  
(Undesirable  effects)  and  5.1 
sections  4.2 
properties 
and” 
5.2 
II-0012 
II-0013 
N-0014 
II/0015 
Change(s)  to  the  test  method(s)  and/or  specifications  for  the  active 
substance 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Renewal of the marketing authorisation 
II/0016 
N/0017 
R/0018 
II 
II 
N 
II 
II 
N 
R 
19.03.03 
30.06.03 
24.07.03 
20.10.03 
08.04.03 
- 
21/01/2004 
25/03/2004 
29/07/2004 
28/05/2004 
- 
- 
23/06/2004 
09/09/2004 
2/2 
EMEA 2004 
 
 
 
